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This phase II study assessed the clinical efficacy and tolerability of a combination of mitomycin C, vinblastine and cisplatin in patients
with metastatic breast cancer (MBC) previously treated with chemotherapy. A total of 87 patients with MBC, most of whom had
been exposed to anthracyclines (92%) and/or taxanes (29%) in the adjuvant and/or metastatic setting, were treated with mitomycin
C( 8m gm
 2 day 1 cycles 1, 2, 4 and 6), vinblastine (6mgm
 2 day 1) and cisplatin (50mgm
 2 day 1) repeated each 21 days for a
maximum of six cycles. The overall response rate (ORR) was 32% (95% CI: 22–42%) with 31% partial response (PR) and one
complete response (CR). Stable disease (SD) rate was 21% (95% CI: 12–29%). There was no statistically significant difference in the
ORR when MVP was given as the first-line treatment for MBC vs second or subsequent line (38 vs 30%, P¼0.6), or between patients
with an early (o6 months) vs late (46 months) relapse post-anthracyclines (30 vs 52%, P¼0.3). Toxicity profile was mild. This
platinum-based chemotherapy is an effective, well-tolerated and low-cost regimen for patients with MBC, including those pretreated
with anthracyclines.
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Breast cancer is the most frequent malignant disease among
Western women. Despite treatment following early stage diagnosis,
a high percentage of patients develop metastatic disease.
Most patients now receive anthracycline-based chemotherapy
regimens in the adjuvant setting, and an increasing number of
them receive taxanes either in this setting or as first-line therapy
for metastatic disease. The majority of patients developing or
presenting with metastatic disease show a good performance
status, making them eligible for systemic cytotoxic drug treat-
ments. The development of new chemotherapy regimens is thus
needed to treat anthracycline and/or taxane-pretreated patients.
A number of previous studies (Kolaric and Roth, 1983; Sledge
et al, 1988; Smith and Talbot, 1992) have demonstrated the efficacy
of cisplatin-based chemotherapy regimens both in previously
untreated patients with metasatic breast cancer, and following
anthracycline failure (Vassilomanolakis et al, 2000; Mustacchi et al,
2002). However, the widespread use of platinum-based treatments
has been undermined by the alleged lower tolerability of these
regimens and the requirement for prolonged infusion protocols.
Some recent preclinical data have suggested a potential higher
benefit for younger patients with BRCA-1 mutation from
platinum-based chemotherapy, given the drug’s mechanism of
action as a DNA-damaging agent to which these patients’ tumours
may be especially sensitive (Husain et al, 1998; Bhattacharyya et al,
2000; Tassone et al, 2003). Some studies have also shown synergy
between cisplatinum and trastuzumab in HER-2-positive breast
cancer (Pegram et al, 1998; Konecny et al, 1999). Hence, there is a
rationale to develop an effective and well-tolerated platinum-based
regimen for metastatic breast cancer (MBC).
Our previous experience with a combination of cisplatin,
vinblastine and mitomycin C (MVP) in lung cancer patients (Ellis
et al, 1995) led us to run a prospective phase II trial to study this
regimen in women with MBC, including those pretreated with
anthracyclines. In addition, a group of patients previously treated
with taxanes were also included.
PATIENTS AND METHODS
Eligibility
Patients were required to have received prior chemotherapy either
in the adjuvant setting or as first-line treatment with a minimal
period of 4 weeks free of disease progression. All patients had
either measurable or evaluable disease. Nonmeasurable but
evaluable disease was defined as malignant disease evident on
physical or radiological examination, but not measurable by ruler
or callipers, for example, locally advanced chest wall disease
evaluated by photography, or multiple small (o1cm) skin
nodules. Patients were required to have Eastern Cooperative
Oncology Group performance status p2, adequate bone marrow
reserve (WBC count X3.5 10
9l
 1, platelets X100 10
12l
 1 and
haemoglobin X10gdl
 1) and satisfactory renal function (creati-
nine clearance X60mlmin
 1 measured by
51Cr EDTA or
Cockcroft and Gault estimation). Liver function tests were allowed
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sup to twice normal values, or five times if liver metastases were
present. No prior cisplatin chemotherapy was allowed, but there
was no limit placed on the number of previous chemotherapy
regimens or endocrine treatments received. The study was
approved by the Royal Marsden Hospital Ethics Committee and
all patients gave written informed consent.
Treatment schedule
The treatment regimen was similar to that previously reported for
patients with non-small-cell lung cancer (11): mitomycin C
8mgm
 2 i.v. day 1 (cycles 1, 2, 4 and 6 only), vinblastine
6mgm
 2 (max 10mg) i.v. day 1 and cisplatin 50mgm
 2 day 1 of
each cycle.
The hydration and diuretic treatment was as follows: prior to
cisplatin: furosemide 40mg i.v. and 1l 0.9% NaCl with 20mmol
KCl and 10mmol MgSO4 over 1h; cisplatin dose was administered
in 1l 0.9% NaCl with 20mmol KCl, 10mmol MgSO4 over 4h and
manitol 100ml 20% i.v; post- cisplatin: 1l 0.9% NaCl with 20mmol
KCl and 10mmol MgSO4 over 2h and then 500ml 0.9% NaCl with
10mmol KCl and 5mmol MgSO4 over 1h. Antiemetic treatment
was delivered prechemotherapy with domperidone 20mg, granise-
tron 1mg and dexamethasone 8mg i.v. and postchemotherapy
with domperidone 10–20mg p.o. qds for 3 days and dexametha-
sone 4mg p.o. tds for 3 days.
The schedule was given as either an in-patient (overnight
admission), or as a day-case and repeated every 3 weeks for a
maximum of six cycles.
Tumour response assessment
Toxicity recording and clinical assessment of tumour response as
well as clinical examination and full blood count test was
performed prior to each cycle. Formal radiological assessment of
response by computed tomography or X-ray was undertaken prior
to study entry, after three cycles and after six cycles or at the end of
treatment if earlier. Standard WHO criteria were used to define
response (this study predated the routine use of RECIST criteria).
Treatment modifications
Treatment was delayed for 1 week if the white cell count
waso3.0 10
9l
 1, or platelets o100 10
12l
 1. Renal function
was assessed at each cycle with plasma urea and creatinine, and
Cockcroft and Gault estimation. If creatinine clearance fell between
40 and 60mlmin
 1, then the cisplatin dose was equivalent to the
creatinine clearance and, if creatinine clearance fell to
o40mlmin
 1, then cisplatin was replaced by carboplatin at a
dose of AUC 5 (AUC¼creatinine clearance or EDTAþ25)
(Smith et al, 2001).
RESULTS
Patient characteristics
Between September 1996 and May 2002, 87 patients diagnosed with
MBC were treated with MVP in this phase II study. The
characteristics of patients are summarised in Table 1. A total of
80 (92%) had previously been treated with anthracyclines, and 25
(29%) with taxanes. Total of 60 patients (69%) had received prior
adjuvant chemotherapy, and 63 (72%) had already received
cytotoxic treatment for MBC. All patients had received at least
one prior chemotherapy regimen.
Clinical efficacy
Data on response to MVP combination are shown in Table 2
analysed on an intention-to-treat (ITT) basis. In all, 27 patients
(31%) showed a partial response (PR), and one (1%) a complete
response (CR) resulting in an overall response rate (ORR) of 32%
(95% CI: 22–42%). A total of 18 (21%, 95% CI: 12–29%) patients
achieved stable disease (SD) as the best response; median duration
20 weeks (95% CI: 12–58 weeks). When MVP was given as the
first-line treatment for MBC, an objective response was obtained in
nine out of 24 patients (38%, 95% CI: 18–57%)) compared with 19
out of 63 (30% (95% CI: 19–41%)) when given as second to sixth
line (Table 2). No statistical difference was seen comparing these
two groups (P¼0.6).
In 31 patients, MVP was given on progression after an
anthracycline-based treatment. These patients relapsed/progressed
early (o6 months since completion of anthracycline therapy either
in the metastatic or adjuvant setting), or later (46 months). A
total of 10 patients were in the former group and 21 in the latter.
No difference in ORR was seen between early and late relapse
groups (30 vs 52%, P¼0.3). In the group of taxane pretreated
patients (all had received taxane as first-line therapy for metasatic
disease), 21 out of 25 were evaluable for response. In these
patients, an ORR of 20% was achieved (95% CI: 4–36%), which
does not reach statistical difference (P¼0.06) when compared with
the general group.
Overall, the median duration of objective response was 7 months
(range: 4–23) in 27 out of the 28 responders; one patient remains
in remission at 35þ months. The median progression-free
survival was 4 months with a median overall survival of 8 months
(Figure 1).
Treatment and toxicity
In total, 350 cycles were delivered in 87 patients with a median
number of 4.02 cycles per patient. Treatment was delivered either
as an in-patient regimen with an overnight stay (the majority), or
as a day-case treatment.
Table 1 Patients characteristics
Patients number 87
Age median in years (range) 50 (32–73)
ER status
Positive 20
Negative 27
Unknown 40
Previous adjuvant therapy
Chemo. only 15 (17%)
Chemo.+Tam 45 (52%)
Tamoxifen only 12 (14%)
None 15 (17%)
No. of previous chemotherapy regimens for MBC
None 24 (28%)
1 36 (41%)
2 21 (24%)
3 or more 6 (7%)
Prior anthracyclines 80 (92%)
Prior taxanes 25 (29%)
Site of metastasis
Soft tissue 80 (92%)
Lung 41 (47%)
Liver 37 (43%)
Pleura 33 (38%)
Bone 31 (36%)
CNS 2 (2%)
ER¼oestrogen receptor; CNS¼central nervous system; MBC¼metastatic breast
cancer; soft tissue includes breast and lymph nodes.
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sData on toxicity are presented in Table 3. In all, 19 cycles out of
a total of 350 were associated with febrile neutropenia (5.5% of
cycles) in 16 patients (18% of patients). Other haematological
toxicity was infrequent. The most common nonhaematological
toxicity was lethargy with a 26% incidence of grade 3. Nausea and
vomiting were not severe in most of the patients, with 11%
presenting with grade 3 and none with grade 4 toxicity.
Neuropathy was always mild and reversible with one only patient
presenting with grade 3 toxicity.
A total of 41 patients required treatment delay at some point,
mainly due to haematological toxicity. In all, 12 patients required a
dose reduction of one or more drugs and 17 patients stopped
treatment due to toxicity, five because of haematological toxicity
and 12 because of nonhaematological toxicity (three cases of
increased liver function tests, two of emesis, two of constipation,
one of decreased glomerular filtration rate, one of acute ischaemic
limb, one of lethargy, one of anxiety and one nonspecified). Nine
patients received less than two cycles due to toxicity (haemato-
logical toxicity in three cases, constipation in two, emesis in one,
raised liver function test in one and lethargy in two). No toxic
deaths occurred.
Drug cost
The actual drug cost for MVP calculated for a patient with 1.7m
2
body surface is around d80 (112h) per cycle.
DISCUSSION
Chemotherapy remains a first-line treatment option for many
patients diagnosed with metastatic breast cancer. With the
increasing use of the most effective drugs in the adjuvant setting,
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Figure 1 Progression-free survival and duration of response curves.
Table 2 Response data: (A) General group; (B) analyses by previous chemotherapy
Response No. of patients % of all patients % of evaluable patients
(A)
CR 1 1 1
PR 27 31 35
OR 28 32 (22–42%) 36 (26–47%)
SD 18 21 23
PD 31 36 40
NE 10 11 —
(B)
No previous chemo. for MBC No. of patients No. of responses % of all patients
Nil 24 9 38 (18–57)
1–5 63 19 30 (19–41)
Previous taxanes 25 5 20 (4–36%)
In brackets, 95% CI; CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progressive disease; OR¼overall response; NE¼nonevaluable;
chemo¼chemotherapy; MBC¼metastatic breast cancer.
Table 3 Worst toxicity, expressed as number of patients, ever observed
in all 87 patients (WHO criteria)
WHO grade 1+2 (%) 3 (%) 4 (%)
Lethargy 50 (57) 22 (25) 0
Nausea/vomiting 48 (55) 11 (13) 0
Alopecia 34 (39) 8 (9) 0
Neuropathy 17 (20) 1 (1) 0
Stomatitis 34 (39) 2 (2) 0
Diarrhoea 16 (18) 5 (6) 0
Infection 22 (25) 22 (25) 0
Anaemia 50 (57) 7 (8) 1 (1)
Leucopenia 41 (47) 11 (13) 7 (8)
Neutropenia 20 (23) 10 (11) 18 (21)
Thrombocytopenia 15 (17) 9 (10) 3 (3)
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sthere is an increasing need to evaluate novel regimens for MBC.
The ideal treatment regimen should cause good symptom control
through maximum tumour regression with a prolonged progres-
sion-free interval and minimal toxicity. Cost-effective regimens are
also advantageous.
Anthracyclines (doxorubicin or epirubicin), either as single
agent or in combination, are one of the most effective agents in the
treatment of breast cancer and are increasingly used in the
adjuvant setting in view of the survival benefit seen over non-
anthracycline regimens (EBCTCG, 1998). Taxanes (paclitaxel and
docetaxel) are the only drugs to have consistently shown similar or
greater activity than doxorubicin in MBC (Chan et al, 1999), and
have been established as the first option after failure of
anthracyclines (Nabholtz et al, 1999). Recent studies (Buzdar
et al, 2002; Nabholtz et al, 2002; Henderson et al, 2003) are leading
to the progressive inclusion of taxanes in the adjuvant treatment
schedules. This means that there will be an increasing number of
MBC patients who present with good performance status, but are
not candidates for retreatment with anthracyclines or taxanes
because of either cardiac tolerance limits, or the likelihood of
resistance to these therapies if they have relapsed within a 6-month
period. Hence, the necessity for effective and well-tolerated
palliative regimens.
Cisplatin has been combined with other agents in an attempt to
derive an active regimen with no overlapping toxicities. Three
studies have tested the combination of this drug with epirubicin
plus or minus lonidamine and failed to show any substantial
benefit from the addition of cisplatin (Gebbia et al, 1997; Dogliotti
et al, 1998; Berruti et al, 2002). Despite being active (response rate
of 73–82% in first line), the addition of cisplatin did not result in
clinical benefit and the toxicity was higher. This latter finding was
confirmed in a Danish study (Nielsen et al, 2000), although these
authors found that survival in the epirubicin plus cisplatin arm
was significantly longer than in the epirubicin only one.
When combined with taxanes, cisplatin has shown a response
rate higher than 80% (Klaassen et al, 1998) although the additive
toxicities, in particular neurotoxicity, have raised serious concerns
about its feasibility (Wasserheit et al, 1996). Of note, most of the
above-mentioned studies reporting high toxicity associated with
cisplatin were based on cisplatin doses of 100mgm
 2 per cycle,
while equally effective in response rates but better tolerance was
seen when dose was between 50 and 60mgm
 2. Carboplatin has
been tested in the same first-line setting and shown better
tolerability in some studies, although less convincing results in
terms of response rate (Kolaric and Vukas, 1991; Brambilla et al,
1993). Two recent reports showed that cisplatin in combination
with vinka-alkaloids may be a very well-tolerated regimen as an
alternative to taxanes after anthracyclines failure (Vassilomanola-
kis et al, 2000; Mustacchi et al, 2002).
Our series was commenced following evidence of good tolerance
to MVP in lung cancer patients (Ellis et al, 1995), and shows very
similar results to those reported above (Vassilomanolakis et al,
2000; Mustacchi et al, 2002). An ORR of 32% in a population of
frequently heavily pretreated patients (92% of patients previously
treated with anthracyclines and 28% with taxanes) is an
encouraging result. The toxicity was mostly mild and tolerable
with only 10% of patients stopping treatment due to toxicity prior
to the third cycle. In addition, this is an active regimen that is
considerably cheaper than taxane-based chemotherapy in this
anthracycline-pretreated population with a drug cost per treatment
cycle of d80, which compares favourably to approximate d1000 for
taxanes-based chemotherapy. Nevertheless, the cost of overnight
or day-case admission, and the specific antiemetic treatments,
should all be considered in a more accurate comparative cost
analyses.
In summary, MVP is a well-tolerated regimen with promising
activity for advanced breast cancer, even in heavily pretreated
patients. For certain groups of patients, its low toxicity makes it an
alternative to taxanes, and MVP may also be a consideration after
taxane failure. Prospective comparisons against other commonly
used treatments in this setting such as vinorelbine or capecitabine
are warranted.
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